How to buy Centogene N-V stock | $9.81

Centogene N.V is a diagnostics & research business based in the US. Centogene N-V shares (CNTG) are listed on the NASDAQ and all prices are listed in US Dollars. Centogene N-V employs 660 staff and has a trailing 12-month revenue of around 0.00.

Centogene N-V stock price (NASDAQ: CNTG)

Use our graph to track the performance of CNTG stocks over time.

Centogene N-V shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$9.81
52-week range	$8.61 - $14.00
50-day moving average	$10.47
200-day moving average	$11.19
Wall St. target price	$20.13
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.05

Buy Centogene N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Centogene N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Centogene N.V by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Centogene N-V price performance over time

Historical closes compared with the close of $9.81 from 2021-05-28

1 week (2021-07-20)	N/A
1 month (2021-07-01)	-8.06%
3 months (2021-04-30)	-9.75%
6 months (2021-01-27)	N/A

1 year (2020-07-27)	N/A
2 years (2019-07-27)	N/A
3 years (2018-07-27)	N/A
5 years (2016-07-27)	N/A

Centogene N-V financials

Revenue TTM	$181.2 million
Gross profit TTM	$46.7 million
Return on assets TTM	-4.25%
Return on equity TTM	-30.59%
Profit margin	-9.67%
Book value	$2.81
Market capitalisation	$253.8 million

TTM: trailing 12 months

Shorting Centogene N-V shares

There are currently 117,712 Centogene N-V shares held short by investors – that's known as Centogene N-V's "short interest". This figure is 56.7% down from 271,760 last month.

There are a few different ways that this level of interest in shorting Centogene N-V shares can be evaluated.

Centogene N-V's "short interest ratio" (SIR)

Centogene N-V's "short interest ratio" (SIR) is the quantity of Centogene N-V shares currently shorted divided by the average quantity of Centogene N-V shares traded daily (recently around 161249.31506849). Centogene N-V's SIR currently stands at 0.73. In other words for every 100,000 Centogene N-V shares traded daily on the market, roughly 730 shares are currently held short.

However Centogene N-V's short interest can also be evaluated against the total number of Centogene N-V shares, or, against the total number of tradable Centogene N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Centogene N-V's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Centogene N-V shares in existence, roughly 10 shares are currently held short) or 0.0191% of the tradable shares (for every 100,000 tradable Centogene N-V shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Centogene N-V.

Find out more about how you can short Centogene N-V stock.

Centogene N-V share dividends

We're not expecting Centogene N-V to pay a dividend over the next 12 months.

Centogene N-V overview

Centogene N. V. , together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.

Frequently asked questions

What percentage of Centogene N-V is owned by insiders or institutions?
Currently 32.689% of Centogene N-V shares are held by insiders and 51.651% by institutions. How many people work for Centogene N-V?
Latest data suggests 660 work at Centogene N-V. When does the fiscal year end for Centogene N-V?
Centogene N-V's fiscal year ends in December. Where is Centogene N-V based?
Centogene N-V's address is: Am Strande 7, Rostock, Germany, 18055 What is Centogene N-V's ISIN number?
Centogene N-V's international securities identification number is: NL0014040206 What is Centogene N-V's CUSIP number?
Centogene N-V's Committee on Uniform Securities Identification Procedures number is: N1976T109